Skip to content
Urupong
- Genmab A/S (GMAB) has been upgraded to Outperform at William Blair on a number of potential late-stage trial pipeline in 2026.
- William Blair analysts say that Johnson & Johnson (JNJ) opting out of development of GEN3014 was unfortunate, but largely
